Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2023-12-26 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
南微医学科技股份有限公司关于开展套期保值业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 南微医学科技股份有限公司 regarding the commencement of hedging (套期保值) business activities. It details the purpose, scope, authorization, risk analysis, and risk control measures related to the hedging business. The document includes board and supervisory committee approvals and independent director opinions. It is a regulatory announcement about a financing risk management activity rather than a financial report, earnings release, or management discussion. The document length is 2663 characters, which is relatively short and consistent with an announcement rather than a full report. There is no financial statement or detailed financial data presented. Therefore, this document fits best under Capital/Financing Update (CAP) as it relates to the company's financing risk management activities and hedging business plans.
2023-12-26 Chinese
南京证券股份有限公司关于南微医学使用部分暂时闲置募集资金进行现金管理之专项核查意见
Regulatory Filings
2023-12-26 Chinese
独立董事意见
Regulatory Filings
2023-12-26 Chinese
南微医学科技股份有限公司关于召开2023年第三季度业绩说明会的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) for investors. It references the prior disclosure of the 2023 third quarter report but does not contain any actual financial data or results itself. The document is short (1479 characters) and serves to inform investors about the upcoming conference call style event with video and online interaction. This matches the characteristics of a Call Transcript (CT) announcement or an Investor Presentation (IP) announcement. However, since it is only announcing the meeting and inviting questions, and not providing the transcript or presentation itself, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. It is not the actual earnings release (ER) or interim report (IR) because it contains no financial data, nor is it a report publication announcement (RPA) because it does not mention the report being attached or published here. Therefore, the best fit is Regulatory Filings (RNS).
2023-11-22 Chinese
南微医学科技股份有限公司2023年第三季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2023 年第三季度报告" which translates to "2023 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and financial metrics for the third quarter and the first nine months of 2023. The document explicitly states it is an unaudited quarterly report and includes comprehensive financial figures and analysis for the quarter. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is about 15,000 characters long, indicating it is the full report, not just an announcement. Therefore, the correct classification is IR with high confidence. 9M 2023
2023-10-27 Chinese
南微医学科技股份有限公司部分高级管理人员集中竞价减持股份结果公告
Director's Dealing Classification · 100% confidence The document is a formal announcement from a company regarding the results of a share reduction plan by a senior management member. It details the shareholding before and after the reduction plan period, the number of shares intended to be sold, and the actual shares sold (which is zero). The document includes specific dates and shareholding percentages but does not contain financial statements or performance data. It is a notification about insider share transactions by a company director/executive. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on share transactions by a director, confirming the classification.
2023-10-27 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.